IP Library Granted Patent US 8,618,331
Granted Patent B2
US 8,618,331 · App. 12/720,448 · Granted Dec 31, 2013

Polycyclic heteroaryl substituted triazoles useful as axl inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,618,331
App. No.
12/720,448
Granted
Dec 31, 2013
Kind
B2
Abstract

Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

Claims (29)

1. A process for preparing an aryl-fused cycloheptanone or a heteroaryl-fused cycloheptanone of formula (i):

wherein Z is an aryl or a heteroaryl and each R 1 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, and optionally substituted heteroarylalkyl;

wherein the process comprises:

a) combining a reactant of formula (ii):

wherein each R 2 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted aralkyl, and optionally substituted heteroarylalkyl, with a reactant of formula (iii):

wherein Z is the aryl or the heteroaryl, as defined above, and each LG is independently a suitable leaving group, in the presence of a protic solvent, an aprotic solvent selected from an ether, and a base to form a product; and

b) subjecting the product of step a) to a basic hydrolytic media followed by acid to form the aryl-fused cycloheptanone or a heteroaryl-fused cycloheptanone of formula (i).

2. The process of claim 1 , wherein Z is phenyl.

3. The process of claim 2 , wherein each R 2 is lower alkyl.

4. The process of claim 3 , wherein each R 1 is hydrogen.

5. The process of claim 4 , wherein each LG is halo.

6. The process of claim 5 , wherein the protic solvent is an alcohol.

7. The process of claim 6 , wherein the base is a metal alkoxide.

8. The process of claim 7 , further comprising exposing the product of step a) to an acidic media prior to step b).

9. The process of claim 8 , wherein step a) is performed within a temperature range of between about −10° C. and about 100° C.

10. The process of claim 8 , wherein step a) is performed within a temperature range of between about 0° C. and about 50° C.

11. The process of claim 8 , wherein step a) is performed within a temperature range of between about 0° C. and about 30° C.

12. The process of claim 11 , wherein the basic hydrolytic media comprises an alcoholic solution of a metal hydroxide or metal alkoxide.

13. The process of claim 11 , wherein the basic hydrolytic media comprises an alcoholic solution of a metal hydroxide.

14. The process of claim 11 , wherein step b) is performed within a temperature range of between about 40° C. and about 150° C.

15. The process of claim 12 , wherein step b) is performed within a temperature range of between about 60° C. and about 100° C.

16. The process of claim 12 , wherein step b) is performed within a temperature range of between about 60° C. and about 100° C.

17. The process of claim 12 , wherein the protic solvent comprises a lower alkanol.

18. The process of claim 17 , wherein the aprotic solvent is THF.

19. The process of claim 18 , wherein each LG is bromo.

20. The process of claim 19 , wherein the acid and the acidic media each independently comprise at least one of an organic acid and an inorganic acid.

21. The process of claim 19 , wherein the protic solvent comprises at least one of methanol and ethanol.

22. The process of claim 21 , wherein the protic solvent is methanol.

23. The process of claim 22 , wherein step a) is performed in about 1:1 methanol to THF.

Assignments (2)
SECURITY INTEREST Recorded May 8, 2026
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 075576/0880 →
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →